Aidan Crawley

Aidan Crawley is the Co-Founder and CEO of Amber Therapeutics, a company dedicated to developing innovative solutions for urinary incontinence through advanced neuromodulation technology. Under his leadership, Amber Therapeutics has made significant strides, including raising $100 million in a Series A funding round, which is one of the largest for a medical technology company in Europe.12

Background and Career

Crawley has a robust background in both finance and technology. Before founding Amber Therapeutics, he served as an entrepreneur-in-residence at Oxford Science Enterprises, where he focused on transforming scientific innovations into successful business ventures. His career has been characterized by a commitment to addressing unmet healthcare needs rather than competing in saturated markets.13

Amber Therapeutics

Amber Therapeutics aims to tackle the challenge of urinary incontinence, which affects over 40 million women in the U.S. alone. The company's technology specifically targets the pudendal nerve, utilizing a unique approach to restore normal bladder function through electrical stimulation. This method promises to offer a comprehensive solution for both major types of urinary incontinence.12

Crawley's vision for Amber Therapeutics reflects his desire to create impactful healthcare solutions that can significantly improve patients' lives, moving beyond incremental advancements to truly transformative therapies.1